Global biopharmaceutical company AbbVie (NYSE:ABBV) reported its fourth-quarter earnings results before the opening bell this morning and pointed to an increasingly difficult environment due to generic competition.

For the quarter, AbbVie delivered worldwide revenue of $5.11 billion, representing a 1.8% decline that includes a negative 0.7% effect for currency translation. Profit for the quarter shrank to a diluted $0.70 per share from $0.98 in the year-ago period as operating profits were negatively affected in the U.S. by the introduction of generic drugs.

The most important pipeline product to AbbVie is Humira, which contributed 59.5% of AbbVie's $5.11 billion in sales this quarter, and finished the year as the best-selling drug in the world with $10.66 billion in revenue. International sales of Humira rose by 8.2% while revenue in the U.S. pushed higher by 18.1%. Total Humira sales increased 13.4% for the quarter.

Within the remainder of AbbVie's product line, Synagis, AndroGel, Kaletra, and Lupron -- which delivered between $209 million and $314 million in revenue for the quarter -- all saw reported sales decline, with AndroGel's 20.9% decline being the steepest.

Looking toward 2014, AbbVie forecasts revenue of approximately $19 billion, which doesn't include any positive impact from the potential approval and launch of its hepatitis C direct-acting antiviral combo drug, and projects earnings per share to range between $3 and $3.10 on an adjusted basis. 


Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy